A non-parametric estimator for excess recurrent events

summary

The gist

Measuring disease burden is an important part of both public health research and health economics.

In short

The paper develops a novel nonparametric estimator to measure excess recurrent events by combining cohort data with population-level data. This method estimates how many extra recurrent events occur beyond what would be expected in a general population without the disease. The results show this estimator is useful for quantifying the burden of diseases with many recurrences, like certain cancers.

Key concepts

Relative Survival
A survival analysis method that adjusts observed survival rates in a specific group (cohort) using data from the entire population. It helps account for differences in mortality rates between groups, allowing researchers to compare outcomes more fairly.
Excess Recurrent Events
This refers to the number of recurrent events (like hospitalizations) that happen more frequently than expected in a population without the specific disease. The estimator aims to quantify this 'excess' burden.
Non-parametric Estimator
A statistical method that does not assume a specific mathematical distribution for the data, unlike parametric methods. This estimator uses product limit estimators to estimate survival and event rates directly from the data, making it flexible for various disease patterns.

Terminology used across episodes

This episode discusses

The paper

A non-parametric estimator for excess recurrent events · Read on arXiv

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet · Department of Mathematics, Stockholm University · Department of Molecular Medicine and Surgery, Karolinska Institutet

Measuring disease burden is an important part of both public health research and health economics. Some measures of disease burden, such as hospitalisations, are made up of recurrent events. Assessing what events are related to a particular disease is however non-trivial. We extend the notion of relative survival to recurrent events by developing a novel non-parametric estimator. The estimator combines data from some cohort with aggregated population level data to estimate the number of excess recurrent events. Using empirical process theory, we show that the estimator converges weakly to a mean zero Gaussian process under mild regularity conditions, and provide a consistent estimator for the covariance function. We also evaluate the finite sample properties of the estimator through simulations and provide a practical example using data from Swedish patients with rectal cancer.

Transcript

Introduction to the show: ident: Statistics. The day in statistics: methods, theory and the inference under them.

Tom: I'm Tom.

Jane: And I'm Jane, here with Lu, Meng and our in-house large language model, Lalam.

Tom: We're looking at the paper: "A non-parametric estimator for excess recurrent events".

Jane: Here's the gist of the paper. Measuring disease burden is an important part of both public health research and health economics.

Tom: This paper extends the notion of relative survival to recurrent events by developing a novel nonparametric estimator.

Jane: The estimator combines data from some cohort with aggregated population level data to estimate the number of excess recurrent events.

Tom: Hospitalisations and other recurrent events occur frequently in epidemiological data.

Paper summary: Tom: Looking at the full title, "A non-parametric estimator for excess recurrent events," it tells you immediately that this work is focused on finding a statistical tool that doesn't rely on assuming a specific mathematical shape for how these events happen Tom. It's about building a method that works without having to pick a fixed model beforehand Jane.

Jane: And the authors, Hedberg and Hössjer, are using this estimator to estimate the number of excess recurrent events by combining data from some cohort with aggregated population level data Lu. The implication is that this gives us a way to quantify how much more often certain events occur in a diseased group compared to what we'd expect from the general public Jane.

Lu: What this means practically is that instead of just counting hospitalizations, you can estimate the actual excess burden on the healthcare system by subtracting what would have happened without those specific disease factors Lu. It helps researchers bypass issues where recorded reasons for events don't accurately capture the total disease impact Tom.

Meng: From a production standpoint, if this method is robust—and they show consistency for the covariance function—it means we can get a more reliable number on how many extra cases you expect to see in a population with that condition Meng. It moves us away from potentially misleading counts based only on labeled reasons Jane.

Lalam: And the paper concludes by showing that this estimator is useful for quantifying the burden of illness across different diseases, even suggesting stratification might be better for individual patient decisions Lalam. It's a general tool for measuring excess events in many contexts Tom.

Jane: So, in simple terms, this paper gives us a statistically sound way to measure the extra events that happen because of a disease compared to normal population trends, even when the reasons are messy Jane. It's about getting a better handle on the real impact of recurrent illness Tom.

Conclusion: Tom: So, we've been looking at this paper titled "A non-parametric estimator for excess recurrent events." Basically, they’ve developed a way to measure how many extra events you see because of a disease compared to what happens in the general population without that disease.

Jane: It sounds like it’s trying to solve the problem where we just count things, but we don't know if those counts truly reflect the total burden of the illness.

Tom: Exactly. And they use this estimator by combining data from a specific group with broader population numbers to figure out that excess number.

Lu: The core idea is decomposing those individual event rates into an excess rate and a general population rate, which lets them estimate the excess part without needing a fixed model for how those events follow over time.

Meng: I'm curious about the practical side—how reliable is this estimate when you actually try to deploy it on real data at scale?

Jane: That’s a good question, Meng. The authors did some simulations, and they showed that the estimator and its error bounds hold up pretty well in tests mimicking real registry scenarios.

Tom: Yeah, I saw those results where the expected number of excess events estimator behaved as expected even with sample sizes of five hundred and two thousand. It seems consistent enough for this kind of work.

Lu: And they proved that the mathematical process they are using converges to a zero mean Gaussian process, which gives them a strong theoretical foundation for how to estimate the uncertainty in their results.

Jane: So, while it’s not a magic fix for everything, it provides a solid framework for quantifying that extra burden on patients and the healthcare system.

Tom: It definitely seems like they're pointing toward using this kind of statistical tool when you need to compare recurrent events against expected population rates for diseases with many recurring issues.

Jane: And this leads us to thinking about what kind of diseases might benefit most from this kind of measurement, especially given the focus on high mortality scenarios.

Meng: It’s interesting that they mention it's relevant for cancers or heart failure—diseases where the recurrence and death rates are both quite high.

Lu: The paper suggests a way to isolate excess recurrent events and excess mortality separately, which is a big step because often those two things get mixed up in standard survival analysis.

Tom: It’s less about finding a single perfect answer and more about building this tool that helps us measure the discrepancy between what we see in a patient group versus the baseline population expectation.

More episodes

← Home